Is autosomal dominant polycystic kidney disease an early sweet disease?

Pediatr Nephrol. 2022 Sep;37(9):1945-1955. doi: 10.1007/s00467-021-05406-z. Epub 2022 Jan 5.

Abstract

The clinical course of autosomal dominant polycystic kidney disease (ADPKD) starts in childhood. Evidence of the beneficial impact of early nephron-protective strategies and lifestyle modifications on ADPKD prognosis is accumulating. Recent studies have described the association of overweight and obesity with rapid disease progression in adults with ADPKD. Moreover, defective glucose metabolism and metabolic reprogramming have been reported in distinct ADPKD models highlighting these pathways as potential therapeutic targets in ADPKD. Several "metabolic" approaches are currently under evaluation in adults, including ketogenic diet, food restriction, and metformin therapy. No data are available on the impact of these approaches in childhood thus far. Yet, according to World Health Organization (WHO), we are currently facing a childhood obesity crisis with an increased prevalence of overweight/obesity in the pediatric population associated with a cardio-metabolic risk profile. The present review summarizes the knowledge about the role of glucose metabolism in the pathophysiology of ADPKD and underscores the possible harm of overweight and obesity in ADPKD especially in terms of long-term cardiovascular outcomes and renal prognosis.

Keywords: Autosomal dominant polycystic kidney disease; Children; Glucose; Insulin; Obesity; Overweight.

Publication types

  • Review

MeSH terms

  • Adult
  • Child
  • Disease Progression
  • Glucose / therapeutic use
  • Humans
  • Kidney
  • Overweight / complications
  • Pediatric Obesity* / complications
  • Polycystic Kidney, Autosomal Dominant* / drug therapy
  • Polycystic Kidney, Autosomal Dominant* / therapy

Substances

  • Glucose